Fairview Capital Partners

Inbox Health Corp. is a digital healthcare company based in New Haven, Connecticut, founded in 2014. It specializes in developing a patient communication platform aimed at medical billers in the United States. The Inbox Health platform automates the patient communication process through bi-directional correspondence and utilizes proprietary algorithms, machine learning, and artificial intelligence. This enables patients to better understand their medical bills and access various payment options. By analyzing a wide range of data points across its customer base, the platform allows billers to personalize the billing, payment, and communication experiences for each patient, ultimately enhancing patient collections and overall satisfaction. The company's mission is to reduce administrative waste in healthcare by streamlining the billing and payment experience for patients.

Inbox Health Corp. is a digital healthcare company based in New Haven, Connecticut, founded in 2014. It specializes in developing a patient communication platform aimed at medical billers in the United States. The Inbox Health platform automates the patient communication process through bi-directional correspondence and utilizes proprietary algorithms, machine learning, and artificial intelligence. This enables patients to better understand their medical bills and access various payment options. By analyzing a wide range of data points across its customer base, the platform allows billers to personalize the billing, payment, and communication experiences for each patient, ultimately enhancing patient collections and overall satisfaction. The company's mission is to reduce administrative waste in healthcare by streamlining the billing and payment experience for patients.

Rallybio is a clinical-stage biopharmaceutical company focused on developing therapies for severe and rare diseases. Its programs cover hematology, immuno-inflammation, maternal-fetal health and metabolic disorders, with a lead candidate aimed at preventing fetal and neonatal alloimmune thrombocytopenia, a life-threatening condition that can cause bleeding in fetuses and newborns. Founded in 2018 and based in New Haven, Connecticut, Rallybio develops therapies across antibodies, small molecules and engineered proteins to address unmet needs in rare diseases. Guided by experienced biopharma leadership, the company emphasizes translating biology into transformative therapies for underserved patients.